

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

HCC44

RRID:CVCL_2060

Type: Cell Line

Proper Citation

RRID:CVCL_2060

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2060

Proper Citation: RRID:CVCL_2060

Description: Cell line HCC44 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:9559342](#), [PMID:10987304](#), [PMID:11314036](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20679594](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29681454](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC44

Synonyms: HCC-44, HCC0044, Hamon Cancer Center 44

Cross References: CLO:CLO_0037012, EFO:EFO_0003133, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:177, BioSample:SAMN03473080, BioSample:SAMN03473528, BioSample:SAMN10988276, cancercellines:CVCL_2060,

Cell_Model_Passport:SIDM01069, ChEMBL-Cells:CHEMBL4295429, ChEMBL-Targets:CHEMBL4296385, Cosmic:877254, Cosmic:903626, Cosmic:1146937, Cosmic:1239870, Cosmic:1995433, Cosmic:2125202, Cosmic-CLP:1240145, DepMap:ACH-000667, DSMZ:ACC-534, DSMZCellDive:ACC-534, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1240145, GEO:GSM108875, GEO:GSM108876, GEO:GSM253314, GEO:GSM434321, GEO:GSM794374, GEO:GSM817110, GEO:GSM827372, GEO:GSM887056, GEO:GSM888126, GEO:GSM1669860, IARC_TP53:28359, IARC_TP53:28435, IGRhCellID:HCC44GEO, KCLB:70044, LiGeA:CCLE_613, LINCS_LDP:LCL-1606, PharmacoDB:HCC44_459_2019, Progenetix:CVCL_2060, PubChem_Cell_line:CVCL_2060, Wikidata:Q54881754

ID: CVCL_2060

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260913T003953+0000

Ratings and Alerts

No rating or validation information has been found for HCC44.

No alerts have been found for HCC44.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. Cell reports. Medicine, 7(2), 102577.

Wang Y, et al. (2025) Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer research, 85(11), 1997.

Lu S, et al. (2025) Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. Molecular cancer therapeutics, 24(6), 920.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. Cell reports. Medicine, 6(10), 102411.

Dissanayake K, et al. (2024) Do extracellular vesicles have specific target cells?; Extracellular vesicle mediated embryo maternal communication. *Frontiers in molecular biosciences*, 11, 1415909.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Geroyska S, et al. (2024) N-Myristoyltransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. *Cancer research communications*, 4(7), 1815.

Munck JM, et al. (2021) ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. *Molecular cancer therapeutics*, 20(10), 1757.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. *Cancer cell*, 39(9), 1214.

Gurtner K, et al. (2020) Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. *International journal of cancer*, 147(2), 472.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Guerra SL, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. *Cancer cell*, 37(5), 705.

Santana-Codina N, et al. (2020) Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics. *Cell reports*, 30(13), 4584.

Janes MR, et al. (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell*, 172(3), 578.